Amgen speaks out about bone density concerns with obesity drug

By Yahoo! Finance   |   2 years ago
Amgen speaks out about bone density concerns with obesity drug

Amgen responded to concerns over bone density loss in its obesity drug candidate, MariTide, following an analyst's comments that caused a market drop. The company stated no association with BMD changes and is set to release Phase II data soon.

Read More

Did you find this insightful?